Nan Fung Group Holdings Ltd Takes $2.96 Million Position in Celcuity, Inc. $CELC

Nan Fung Group Holdings Ltd purchased a new stake in shares of Celcuity, Inc. (NASDAQ:CELC) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 28,300 shares of the company’s stock, valued at approximately $2,960,746. Celcuity comprises approximately 0.0% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 13th biggest position. Nan Fung Group Holdings Ltd owned 0.06% of Celcuity as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its stake in Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after purchasing an additional 319 shares during the last quarter. US Bancorp DE boosted its position in Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Celcuity by 78.9% during the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the last quarter. Parallel Advisors LLC acquired a new position in Celcuity during the 1st quarter valued at approximately $38,000. Finally, Meeder Asset Management Inc. bought a new position in shares of Celcuity in the fourth quarter valued at $42,000. Institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a research report on Monday, August 17th. Guggenheim increased their price target on Celcuity from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Citizens Jmp reissued a “market outperform” rating and set a $177.00 price objective on shares of Celcuity in a research report on Monday, August 17th. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. Finally, Wells Fargo & Company dropped their price target on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $154.55.

Celcuity Stock Down 5.0%

NASDAQ CELC traded down $4.62 on Friday, reaching $88.62. The stock had a trading volume of 275,981 shares, compared to its average volume of 1,086,057. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of -20.61 and a beta of 0.20. The business has a 50 day moving average price of $94.63 and a 200 day moving average price of $107.28. Celcuity, Inc. has a 1 year low of $44.42 and a 1 year high of $151.02.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). On average, analysts forecast that Celcuity, Inc. will post -4.75 EPS for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.